Overview

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Status:
Completed
Trial end date:
2016-12-09
Target enrollment:
Participant gender:
Summary
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dose and tumor type for later-stage clinical trials.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation